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A positive correlation between length of bowel resected and risk of 
BAM would improve the consenting process for surgery. Patients 
would be better informed about the risks of BAM diarrhoea post-
surgery and guide treatment options.
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Background: There is a paucity of data from large cohort studies on 
the prevalence and type of extraintestinal manifestations in pediatric 
patients with Crohn's disease (CD) and ulcerative colitis (UC). We 
aimed to assess the prevalence and type of EIM in pediatric patients 
with inflammatory bowel disease (IBD).
Methods: Data from patients enrolled in the Pediatric Swiss IBD 
Cohort Study (P-SIBDCS) were analyzed. Since 2008 the P-SIBDCS 
collects data on patients aged 2-17 from hospitals and private prac-
tices across Switzerland. Results of continuous data are reported as 
median and interquartile range.
Results: A total of 266 pediatric IBD patients were recruited (146 
[54.9%] with CD, 63% boys, median [interquartile] age at diagno-
sis 12 [9.9-13.6] years, median age at enrollment 13.6 [11.7-15.3] 
years, median disease duration 3.3 [1.6-4.9] years, and 120 [45.1%] 
with UC, 47.5% boys, median age at diagnosis 11.5 [8.2-13.6] years, 
median age at enrollment 13.5 [10.9-15.3] years, median disease 
duration 3.2 [1.6-5.7] years. A total of 90 patients (33.8%) suffered 
from one to a maximum of three EIM during their disease course 
(74/90 patients [82.2%] had one EIM, 14/90 patients [15.6%] had 
two EIM, and 2/90 patients [2.2%] suffered from three EIM. EIM 
were more frequently observed in CD patients (61/146, 41.8%) when 
compared to UC patients (29/120, 242%, p < 0.001). The following 
types of EIM were observed: 37/266 (13.9%) peripheral arthritis / 
arthralgia (17.8% in CD vs. 9.2% in UC); 5/266 (1.9%) uveitis / iri-
tis (2.7% in CD vs. 0.8% in UC; 26/266 (9.8%) oral aphthous ulcers 
(12.3% in CD vs. 6.7% in UC); 2/266 (0.8%) ankylosing spondylitis 
(0.7% in CD vs. 0.9% in UC); 5/266 (1.9%) erythema nodosum 
(2.7% in CD vs. 0.8% in UC); 2/266 (0.8%) pyoderma gangreno-
sum (0.7% in CD vs. 0.8% in UC).
Conclusions: EIM appear in pediatric IBD patients in similar 
prevalence when compared to the adult population. As a general 
rule, EIM are more frequently observed in pediatric CD patients 
when compared to pediatric UC patients. The most frequent EIM 
are peripheral arthritis / arthralgia, followed by oral aphthous 
ulcers.
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Background: Screening for latent tuberculosis infection (LTBI) before 
starting therapy with anti tumor necrosis factor (anti-TNF) antibod-
ies has decreased the risk of active tuberculosis. Corticosteroids (CS) 
or immunosuppressive (IS) therapy may affect the performance of 
the Tuberculin skin test (TST). The aim of this study was to deter-
mine the likelihood of detecting LTBI using a 2-step TST in two 
cohorts of patients with inflammatory bowel diseases: candidates 
and non-candidates for anti-TNF therapy. We also analyzed factors 
associated with the performance of the TST.
Methods: This prospective multicenter case-control study included 
240 consecutive patients selected for anti-TNF therapy and 326 con-
trols. LTBI risk factors were recorded and patients underwent chest 
X-ray and 2-step TST. TST was considered positive if induration was 
≥ 5 mm in the first or the second (booster) test. Factors associated 
with TST Results were analyzed by logistic regression.
Results: Ninety-three of 566 patients (16.4%) had a positive 
TST (21/93 [22.6%] in the second test). Twenty-three of 240 
(9.6%) patients in the anti-TNF group and 70 of 326 (21.5%) 
in the control group had a positive TST (odds ratio [OR] 0.39; 
95% confidence interval [CI] 0.23-0.64; p<0.001). The propor-
tion of Crohn´s disease patients was higher in the anti-TNF 
group (169/240 [70.7%] vs. 180/326 [56.3%]; p=0.002). More 
anti-TNF group patients were receiving CS therapy (37.6% vs. 
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